% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Yan:282539,
      author       = {Yan, Shijun and Sahoo, Anis and Zerenner, Tanja and Marek,
                      Kenneth and Sommerauer, Michael and Oertel, Wolfgang and Hu,
                      Michele T. and Tofaris, George K.},
      title        = {{S}erum p‐tau217 {I}s a {P}rognostic {I}ndicator of
                      {C}ognitive {I}mpairment in {I}diopathic {REM} {S}leep
                      {B}ehavior {D}isorder},
      journal      = {Annals of neurology},
      volume       = {Advance online publication},
      issn         = {0364-5134},
      address      = {Hoboken, NJ},
      publisher    = {Wiley-Blackwell},
      reportid     = {DZNE-2025-01302},
      pages        = {-},
      year         = {2025},
      abstract     = {Assess the performance of serum phosphorylated tau 217
                      (p-tau217) and neurofilament light chain (NfL) in predicting
                      risk of cognitive impairment or phenoconversion to dementia
                      in individuals with iRBD.We measured serum p-tau217 and NfL
                      levels by electrochemiluminescence across 4
                      polysomnographically confirmed iRBD cohorts (n = 300),
                      including individuals who phenoconverted to Parkinson's
                      disease (PD) (n = 51), dementia with Lewy bodies (DLB) (n =
                      22), and multiple system atrophy (MSA) (n = 5).Serum
                      p-tau217 levels were increased in individuals with iRBD and
                      cognitive impairment (CI) on testing defined as Montreal
                      Cognitive Assessment <26 or subthreshold parkinsonism.
                      p-Tau217 differentiated individuals with iRBD who developed
                      PD with CI (PD-CI) or DLB from PD phenoconverters with
                      normal cognition (area under curve [AUC] = 0.82; $95\%$
                      confidence interval, 0.70-0.93) and from iRBD
                      non-phenoconverters with normal cognition (AUC = 0.83;
                      $95\%$ confidence interval, 0.77-0.89). NfL levels did not
                      correlate with cognitive or motor scores and marginally
                      improved p-tau217 performance (AUC = 0.85; $95\%$ confidence
                      interval, 0.78-0.92), but were notably elevated in iRBD
                      individuals who phenoconverted to MSA. Individuals with
                      p-tau217 in the top quartile were 8 times more likely to
                      phenoconvert to PD-CI or DLB compared to the bottom quartile
                      (hazard ratio = 8.30; $95\%$ confidence interval,
                      2.49-27.65).Serum p-tau217, but not NfL, is a useful
                      biomarker of cognitive impairment in iRBD that could be
                      integrated into a multimodal prognostic indicator when
                      stratifying risk of phenoconversion. ANN NEUROL 2025.},
      cin          = {AG Petzold},
      ddc          = {610},
      cid          = {I:(DE-2719)1013020},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1002/ana.78109},
      url          = {https://pub.dzne.de/record/282539},
}